American Society of Hematology. (2019).
FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-grants-accelerated-approval-to-zanubrutinib-for-mantle-cell-lymphoma.
American Society of Hematology.
"FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-grants-accelerated-approval-to-zanubrutinib-for-mantle-cell-lymphoma
(label-accessed April 23, 2024).
"American Society of Hematology."
FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma, 23 Apr. 2024 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-grants-accelerated-approval-to-zanubrutinib-for-mantle-cell-lymphoma.
